BioCryst Pharmaceuticals BCRX Decrease in royalty financing obligations
Decrease in royalty financing obligations at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept bcrx:IncreaseDecreaseInRoyaltyFinancingLiabilities.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's decrease in royalty financing obligations.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's decrease in royalty financing obligations?
- BioCryst Pharmaceuticals (BCRX) reported decrease in royalty financing obligations of -$8.47M in Q1 2026.
- How has BioCryst Pharmaceuticals's decrease in royalty financing obligations changed year-over-year?
- BioCryst Pharmaceuticals's decrease in royalty financing obligations increased by 41.8% year-over-year, from -$14.55M to -$8.47M.
- What does decrease in royalty financing obligations mean?
- Tracks the net change in liabilities associated with royalty-based financing, excluding non-cash interest components. This metric reflects cash inflows from new financing or cash outflows from principal repayments related to royalty obligations. It provides transparency into how the company is utilizing future revenue streams to fund current operations or debt reduction.